A new study reveals that ensifentrine, a novel COPD treatment, significantly reduces COPD-related healthcare usage over 48 ...

Discover the latest insights from the TOReTO study on COPD management: Dual bronchodilator therapy has been shown to reduce exacerbations, with varying efficacy between current and former smokers.

Chronic Obstructive Pulmonary Disease (COPD): For those with COPD, exposure to pollutants can worsen symptoms ... Immediate ...

Ohtuvayre™ (ensifentrine) is the Company’s first commercial product and the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti ...

Q3 2024 Earnings Conference Call November 4, 2024 9:00 AM ETCompany ParticipantsDavid Zaccardelli - President and ...

Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3Through October more than 2,200 unique ...

As AstraZeneca’s chronic obstructive pulmonary disease drug Breztri continues climbing toward blockbuster status, the Big Pharma is broadening its efforts to support people with COPD.

It’s something Lindsay Bishop is seeing more and more of in her role as COPD educator for Open Airways. COPD is a chronic lung condition characterised by swollen, inflamed airways and excessive ...

If advised by a healthcare provider, bronchodilators, which help in keeping the airways open, can make breathing easier ...

As reported by the Central Pollution Control Board's SAMEER app, Mumbai's Air Quality Index (AQI) on Sunday was 157, which ...

Discontinuing medical treatment can trigger asthma attacks, so regular check-ups are essential for managing the condition.

LONDON and RALEIGH, N.C., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a biopharmaceutical company focused on respiratory diseases, announces ...